RFAM merger with HCC Healthcare Pte. Ltd.
HCC Healthcare Pte. Ltd.
Announced 9 July 2026.
HCC Healthcare Pte. Ltd. is a Singapore-incorporated exempt private company that operates through consolidated subsidiaries in Taiwan, forming one of the largest integrated medical and long-term care platforms on the island. The group traces its origins to a single obstetrics clinic founded by Dr. Hsiao Chung-Cheng, and over more than three decades of clinical heritage has evolved into a comprehensive healthcare ecosystem spanning Northern, Central, and Southern Taiwan. On a pro forma combined basis, the network encompasses more than 120 long-term care facilities and over 9,000 licensed beds, including one of the largest caregiving institutions in Taiwan with more than 1,300 beds, operated under a distinctive "hospital-within-an-eldercare-institution" ecosystem model. The group also provides community- and home-based case management for over 7,000 individuals, concentrated in Northern Taiwan, a region representing roughly one-third of the country's population. Its service offerings span medical care, long-term care, caregiver support, rehabilitation, hemodialysis, pharmaceutical services, infection control, nutritional support, social work, medical transportation, consumables procurement, and medical education and consulting.
The company is organized around four strategic business segments: a regional healthcare network anchored by Hsiao Chung-Cheng Hospital (a Grade A NHI-accredited facility), an AI technology platform, a smart long-term care and pharmacy chain operated through Fu Ze Health (a TriHealth subsidiary), and TriHealth Enterprise, which serves as the operational backbone for centralized procurement, logistics, and a long-term care transport fleet. HCC's AI platform leverages an exclusive partnership with Taiwan's National Center for High-Performance Computing for federated learning across all facilities, alongside robotic pharmacy dispensing, a real-time digital twin operational model, predictive analytics for chronic disease management, AI-powered clinical documentation, and a franchise engine designed for capital-efficient site rollouts. The group's strategic growth roadmap centers on four priorities: deploying its proprietary AI platform integrating spatial intelligence and multimodal clinical data, expanding into Japan leveraging existing infrastructure and Japan's regenerative medicine regulatory framework, developing cross-sector partnerships with fitness and wellness operators for preventive and chronic disease care pathways, and accelerating investment in precision and regenerative medicine including AI-driven biomarker profiling.
HCC Healthcare is led by Chief Executive Officer Jack Hsiao, while the SPAC side is headed by Tse Meng Ng, CEO of RF Acquisition Corp III, who also serves as Chief Advisor of DH Wealth Management and played a pivotal role in structuring and executing the transaction. The Singapore holding entity was formally incorporated on September 9, 2025, though the underlying operating group claims over five decades of healthcare heritage. The business combination with RF Acquisition Corp III (Nasdaq: RFAM) values HCC Healthcare at approximately US$500 million on a fully diluted equity basis, with a per-share reference value of US$10.00 following a pre-closing recapitalization. The deal is expected to close in the fourth quarter of 2026, subject to shareholder approvals, effectiveness of a Form F-4 registration statement, and Nasdaq or NYSE listing approval. Certain HCC shareholders and the SPAC founder Alfa 30 have signed voting support and lock-up agreements of up to six months post-closing, and the post-closing board will comprise seven directors, six from HCC and one from Alfa 30 Limited. EarlyBirdCapital is advising RF Acquisition, while K&L Gates and PricewaterhouseCoopers Legal are serving as U.S. and Taiwan counsel respectively to HCC Healthcare, with Bedrock Investment acting as strategic consultant to the company.
HCC Healthcare is pursuing a SPAC merger rather than a traditional
Structure & dilution
SEC-primary termsThe headline number ignores the shares that did not pay $10 — the founder promote, PIPE stock and warrants. This is the same deal with all equity claims counted.
Effective equity counts every claim on the post-close company at $10.00 — rollover, public shares, the founder promote and the PIPE. The headline counts only the target.
- Sponsor promote
- 28%
- Exchange ratio
1:1 plus rights. Each RFAC III ordinary share is cancelled and converted into one newly issued HCC Healthcare Ordinary Share; each RFAC III Right is exchanged for one-tenth (1/10th) of one Company Ordinary Share. HCC Healthcare shares are recapitalized to $10.00 per share off a $500,000,000 fully-diluted equity value.more ▾less ▴
No committed PIPE at signing. The Business Combination Agreement (Section 9.7) only obliges the parties to use reasonable best efforts to obtain transaction financing of $75,000,000 in total, which mamore ▾less ▴
Why headline and effective values differ is covered in headline vs effective deal value, in plain English.
The target: HCC Healthcare Pte. Ltd.
from 425The business actually being bought — described from SEC primary filings, with projections labelled as projections.
HCC Healthcare Pte. Ltd. — every SPAC that has bid for it, and its listed peers
Expensive or cheap?
A price only means something next to what the same kind of business costs on the stock market. This divides what the buyers are paying by what HCC Healthcare Pte. Ltd. actually sells, and sets the answer against its closest listed comparables — or says plainly when that cannot be done.
SpacBrain’s read on the price
No multiple can be computed
We hold no revenue figure in US dollars for HCC Healthcare Pte. Ltd., so there is nothing to divide the price by and no multiple can be struck. It is not recorded as pre-revenue either — this is a gap in our record, not a finding that the company has no sales. The deal values it at $639.3M regardless.
We have not extracted a revenue figure for this company from its filings yet. That is our gap, not a statement about the business.
Post-dilution equity (net debt unknown).
Not extracted from the filings yet.
Not computable — no revenue figure has been extracted from the filings yet.
No listed comparable carries a revenue multiple we can use.
What qualifies the figures above
- Struck on the post-dilution value of $639.3M, not the announced $500M — new shares handed to the sponsor, warrant holders and the PIPE are part of what public buyers are really paying.
- The target's cash and debt are not in the filings we have, so this is an equity value used as a stand-in for enterprise value.
In plain English
No floor / floorlessthe cash guarantee is gone — the price is unprotected
A SPAC's downside protection is not the cash in trust; it is your right to demand that cash. Once the redemption window closes, the cash stays with the company and the share can trade anywhere.
Dilutionhow much of the company new shares take from you
Sponsor promote, PIPE shares, warrants and rights all issue stock that did not pay $10 for it. The headline deal value is before that; the effective value is after.
Pro-forma equitywhat the company is valued at once the deal closes
The combined company's equity value assuming the announced terms and the redemptions that have actually happened.
De-SPACthe day the SPAC becomes the real company
The shares stop being a claim on a pot of cash and start being equity in an operating business. Roughly 80% of recent de-SPACs traded below $10 within a year.
Outside datethe contractual long-stop for closing the deal
A deadline between the SPAC and its target, not between the SPAC and you. It confers no right to cash, which is exactly why it must never be counted as a redemption window.